Ligand Pharmaceuticals (LGND) Change in Cash (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Change in Cash data on file, last reported at -$59.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 146.04% year-over-year to -$59.8 million; the trailing twelve-month figure through Mar 2026 stood at $67.1 million (up 3289.4% YoY), and the FY2025 full-year result was $102.6 million, up 107.93% from the prior year.
• Change in Cash slipped to -$59.8 million in Q1 2026, from $35.6 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $71.7 million in Q3 2025 to a low of -$60.3 million in Q2 2023.
• A 5-year average of $5.6 million and a median of $3.1 million in 2023 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash soared 1146.58% in 2022 and sank 637.71% in 2023, its largest moves.
• Tracing LGND's Change in Cash over 5 years: stood at $40.9 million in 2022, then slumped by 92.43% to $3.1 million in 2023, then jumped by 180.62% to $8.7 million in 2024, then surged by 309.2% to $35.6 million in 2025, then tumbled by 268.3% to -$59.8 million in 2026.
• Business Quant data shows LGND's Change in Cash at -$59.8 million in Q1 2026, $35.6 million in Q4 2025, and $71.7 million in Q3 2025.